Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06932081 · ClinicalTrials.gov registry record
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
A clinical trial of Congenital Heart Disease and Single-ventricle, sponsored by Leiden University Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 11
- Study locations
NCT06932081 is a study of Congenital Heart Disease and Single-ventricle that is actively recruiting participants, run by Leiden University Medical Center. The registered enrollment target is 400 participants, below the 468-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (15% lower). The trial reports 11 study locations across 5 states.
The verdict
NCT06932081, a study of Congenital Heart Disease and Single-ventricle, is actively recruiting participants, sponsored by Leiden University Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 11
- Study locations
Study Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Conditions Studied
Interventions
- DRUG SGLT2 inhibitors
Study Locations (11)
Other
- Heart Center Duisburg (Evangelical Hospital Niederrhein) - Duisburg
- Amsterdam University Medical Center - Amsterdam
- University Medical Center Utrecht - Utrecht
- Zan Mitrev Clinic - Skopje
- University Hospital of Wales - Cardiff
- Golden Jubilee University National Hospital - Glasgow
- Barts Heart Centre - London
Maryland
- Johns Hopkins University - Baltimore
Michigan
- Helen DeVos Children's Hospital - Grand Rapids
New York
- Mount Sinai Fuster Heart Hospital - New York
South Holland
- Leiden University Medical Center (LUMC) - Leiden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06932081
The ClinicalTrials.gov registry entry for NCT06932081 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 468-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (15% lower). The listed sponsor is Leiden University Medical Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which SGLT2 inhibitors is the first listed.
NCT06932081 reports 11 study locations spanning 5 distinct geographic areas - top geographies include Other, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT06932081 about?
NCT06932081 is a clinical study titled "Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry". This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failur...
What is the current status of trial NCT06932081?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2023-01-01. Estimated completion is 2027-12-31.
What conditions does trial NCT06932081 study?
This clinical trial studies the following conditions: Congenital Heart Disease, Single-ventricle, Adult Congenital Heart Disease, Tetralogy of Fallot (TOF), Fontan.
What interventions are being tested in trial NCT06932081?
The interventions under investigation include: SGLT2 inhibitors (DRUG).
Who is sponsoring clinical trial NCT06932081?
This trial is sponsored by Leiden University Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06932081 being conducted?
This trial has 11 study locations across Maryland, Michigan, New York, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fontan Fitness Trial
RECRUITING · NA
-
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
RECRUITING
-
A Study of Invasive Hemodynamic for MACHD Registry
RECRUITING
-
Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables
RECRUITING
-
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
RECRUITING
-
PDA for Kidneys Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.